Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGynecological OncologyNeuro-OncologyDiseaseBreast CancerMalignant MeningitisSubgroupHER2+ICD10C50.-C79.3MeSHBreast NeoplasmsMeningeal CarcinomatosisSequenceTRAS80, Malignant Meningitis, C1 (PID2526) -|- C2 (PID2527) -|- C3+ (PID2542)ChemotherapyChemo-substanceTopotecanTrastuzumabChemo-substanceTopotecanTrastuzumabChemo-substanceTopotecanTrastuzumabChemo-substanceTopotecanTrastuzumabNo. Substances1 RadiotherapySupportive therapySupportive substanceDexamethasoneGranisetronPrednisoloneSupportive substanceDexamethasoneGranisetronPrednisoloneSupportive substanceDexamethasoneGranisetronPrednisoloneSupportive substanceDexamethasoneGranisetronPrednisoloneNo. Substances12Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseInductionMaintenanceTherapy intentionpalliativeRisksAllergic ReactionArachnoiditisEmetogenicity (ASCO)HeadacheNauseaSeizuresVomiting only studiesPublicationAuthorGroves MKumthekar POberkampf FDiseaseLeptomeningeale Metastasen beim Mamma-Ca, HER2+, ECOG 0-3Leptomeningeale Metastasen beim Mamma-Ca, HER2+, Karnofsky >50Refraktäre Meningeosis neoplastica, Erstlinie für Meningeosis neoplastica, Karnofsky > 60OriginDepartment of Neurology at The Feinberg School of Medicine at Northwestern University, USDepartment of Oncology, Institut Curie-St Cloud, FranceUniversity of Texas M. D. Anderson Cancer Center, Houston, TXProtocols in Revision 5 protocols foundProtocols under revision.Topotecan 0.4, Malignant Meningitis (PID2520 V1.0)Trastuzumab 150, Malignant Meningitis (PID2523 V1.0)Trastuzumab 80, Malignant Meningitis, Cycle 1 (PID2526 V1.0)Trastuzumab 80, Malignant Meningitis, Cycle 2 (PID2527 V1.0)Trastuzumab 80, Malignant Meningitis, Cycle 3+ (PID2542 V1.0)
